Deoxycytidine kinase mRNA expression in childhood acute lymphoblastic leukemia

Anticancer Drugs. 1997 Jun;8(5):517-21. doi: 10.1097/00001813-199706000-00015.

Abstract

Initial and relapsed childhood acute lymphoblastic leukemias (ALL) were investigated for mutations and expression of deoxycytidine kinase (dCK). dCK mediating toxicity of 1-beta-D-arabinofuranosylcytosine was analyzed semiquantitatively by RT-PCR and by single-strand conformation polymorphism. We found that patients with initial ALL experienced more frequently a relapse if dCK expression was low or absent. No mutations were found in initial and relapsed ALL.

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Asparaginase / therapeutic use
  • Cells, Cultured
  • Child
  • Daunorubicin / therapeutic use
  • Deoxycytidine Kinase / biosynthesis*
  • Humans
  • Mutation
  • Polymerase Chain Reaction
  • Polymorphism, Single-Stranded Conformational
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / enzymology*
  • Prednisone / therapeutic use
  • RNA, Messenger / analysis
  • RNA, Messenger / biosynthesis*
  • Vincristine / therapeutic use

Substances

  • RNA, Messenger
  • Vincristine
  • Deoxycytidine Kinase
  • Asparaginase
  • Prednisone
  • Daunorubicin

Supplementary concepts

  • PVDA protocol